Scorpius Holdings, Inc (NYSE American:SCPX) (“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced a strategic partnership with a U.S.-based biotech company. Under this ...
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.
The posters are available on the Posters and Publications page of the Company’s website.